Your session is about to expire
← Back to Search
Diagnostic Test
Synuclein-One Study
N/A
Waitlist Available
Led By Todd Levine, MD
Research Sponsored by CND Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group
Summary
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Eligible Conditions
- Autonomic Failure
- Multiple System Atrophy
- Dementia
- Parkinson's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
1
2
3
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
5Treatment groups
Experimental Treatment
Group I: Pure Autonomic FailureExperimental Treatment1 Intervention
Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
Group II: Parkinson's diseaseExperimental Treatment1 Intervention
Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
Group III: Multiple System AtrophyExperimental Treatment1 Intervention
Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
Group IV: Healthy ControlsExperimental Treatment1 Intervention
No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
Group V: Dementia with Lewy bodiesExperimental Treatment1 Intervention
Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Skin Biopsy
2015
Completed Phase 4
~680
Find a Location
Who is running the clinical trial?
CND Life SciencesLead Sponsor
3 Previous Clinical Trials
260 Total Patients Enrolled
Todd Levine, MDPrincipal InvestigatorCND Life Sciences: www.cndlifesciences.com
2 Previous Clinical Trials
110 Total Patients Enrolled